|
More good news these days comes from our advancements against the Covid-19 coronavirus, which a month ago was still threatening to dismantle our economic rebound with the Delta variant, especially in under-vaccinated regions of the U.S. But vaccine mandates in both public and private sectors are having a positive effect, as are developments among vaccine makers. After recommendations about being able to mix and match Covid vaccines as convenient earlier this week, a new Pfizer PFE news item has hit the tape this morning.
While Pfizer and partner BioNTech BNTX still await an FDA ruling until at least an advisory meeting next week, the companies announce 90.7% efficacy among children aged 5-11 in a recent study. This brings the possibility of being able to vaccinate younger kids from Covid earlier than many had previously thought — perhaps as early as the first weeks of November. The study was conducted July through September — when the Delta variant was rampant — and still brought protection to a vast majority of children in the study. |
评分
-
1
查看全部评分
-
|